Trastuzumab emtansine, [7][8] sold under the brand name Kadcyla, is an antibody-drug conjugate consisting of the humanized monoclonal antibody trastuzumab (Herceptin) covalently linked to …

Kadcyla (T-DM1) is a targeted therapy used to treat HER2-positive metastatic breast cancer. Learn more about Kadcyla.

2019年5月23日 · Ado-trastuzumab emtansine (Kadcyla), or T-DM1, has been approved by FDA for use as adjuvant therapy in some women with early-stage HER2-positive breast cancer.

2012年11月8日 · Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that incorporates the HER2-targeted antitumor properties of trastuzumab with the cytotoxic activity …

2018年12月5日 · Trastuzumab emtansine (T-DM1), an antibody–drug conjugate of trastuzumab and the cytotoxic agent emtansine (DM1), a maytansine derivative and microtubule inhibitor, …

Trastuzumab emtansine is the drug’s non-branded name. You may hear it called Kadcyla, its brand name, or TDM1, its chemical name. Trastuzumab emtansine is a combination of 2 …

2019年12月16日 · Despite its objective activity, intrinsic and acquired resistance to T-DM1 remains a major clinical challenge. T-DM1 mediates its activity in a number of ways, …

2014年6月26日 · Ado-trastuzumab emtansine (T-DM1) is an antibody–drug conjugate that combines the antitumor properties of the humanized anti-human epidermal growth factor …

Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate comprising trastuzumab and DM1, a microtubule polymerization inhibitor, covalently bound via a stable thioether linker. To …

2017年6月14日 · Trastuzumab emtansine, an antibody–drug conjugate commonly abbreviated as T-DM1, improved overall survival for women and men with HER2-positive metastatic breast …